In addition, the PI3K/mTOR dual inhibitor gedatolisib combined with immune checkpoint inhibitors (ICI) more significantly inhibited the growth of breast cancer cells and continuously induced the responses of dendritic cells, CD8 + T cells, and NK cells, indicating that the inhibition of PI3K–AKT pathway may enhance breast cancer response to ICIs [119]. Here, MTOR is linked to breast carcinoma.